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Antibiotics are typically more effective against repli-
cating rather than nonreplicating bacteria. However,
amajor need in global health is to eradicate persistent
or nonreplicating subpopulations of bacteria such as
Mycobacterium tuberculosis (Mtb). Hence, identify-
ing chemical inhibitors that selectively kill bacteria
that are not replicating is of practical importance. To
address this, we screened for inhibitors of dihydroli-
poamide acyltransferase (DlaT), an enzyme required
by Mtb to cause tuberculosis in guinea pigs and
used by the bacterium to resist nitric oxide-derived
reactivenitrogen intermediates, a stress encountered
in the host. Chemical screening for inhibitors of Mtb
DlaT identified select rhodanines as compounds
that almost exclusively kill nonreplicating mycobac-
teria in synergy with products of host immunity,
such as nitric oxide and hypoxia, and are effective
on bacteria within macrophages, a cellular reservoir
for latent Mtb. Compounds that kill nonreplicating
pathogens in cooperation with host immunity could
complement the conventional chemotherapy of in-
fectious disease.
INTRODUCTION
Most antibiotics target biosynthetic processes that bacteria
need to increase their biomass (Walsh, 2003). It is not surprising
that such antibiotics are more effective against replicating than
nonreplicating bacteria (Hobby and Lenert, 1957; Levin and Ro-
zen, 2006). However, a major need in global health is to eradicate
persistent or nonreplicating subpopulations of bacteria such as
Mtb (McCune et al., 1966; Munoz-Elias et al., 2005; Rogerson
et al., 2006). Worldwide, an estimated 1 person in 3 is infected
with Mtb; in about 9 of every 10 infected, Mtb persist in a largely
nonreplicating (‘‘latent’’) state throughout the lifetime of the host.
If the immune response flags, Mtb can resume replication andCegive rise to tuberculosis, a contagious disease that kills more
people than any other bacterial infection. Nonreplicating Mtb
are also problematic in clinically active tuberculosis (Boshoff
and Barry, 2005). The acidic phagosomal environment and ‘‘ni-
troxidative’’ (Lancaster, 2004) chemistry generated by the mac-
rophages in which Mtb resides and the deprivation of oxygen
and nutrients that may result from the accumulation of inflamma-
tory cells at infected sites can each keep Mtb from replicating
(Voskuil et al., 2003). Nonreplicating Mtb display nonheritable
antibiotic resistance, also called phenotypic tolerance, a phe-
nomenon that pertains to most members of a bacterial popula-
tion starved for nutrients, as well as to a small, nonreplicating
fraction of a population undergoing logarithmic expansion (Levin
and Rozen, 2006). Durable cure of tuberculosis requires eradica-
tion of both replicating and nonreplicating Mtb (McCune et al.,
1966). During treatment of tuberculosis, nonreplicators termed
‘‘persisters’’ may be responsible for relapse rates that only fall be-
low 5% when chemotherapy is extended for many months. Such
prolonged treatment is difficult to sustain, and its interruption
fosters the emergence of mutants with heritable drug resistance.
That most antibiotics act preferentially against replicating bac-
teria may be a consequence of the way these compounds have
been sought: by screening against pathogens in vitro under con-
ditions that sustain rapid growth and assaying for inhibition of
that growth (Nathan, 2004). In contrast, here we screened for in-
hibitors of an enzyme that Mtb uses to resist a stress it encoun-
ters in the host, nitric oxide-derived reactive nitrogen intermedi-
ates (RNI) (Nathan and Ehrt, 2004). In vitro, RNI at low levels or
short exposures prevent Mtb from replicating, while higher con-
centrations or longer exposures kill it (Nathan and Ehrt, 2004).
One mycobacterial defense against RNI is a peroxynitrite re-
ductase and peroxidase (Bryk et al., 2000). Its four components
are a peroxiredoxin, alkylhydroperoxide reductase subunit C
(AhpC) (Bryk et al., 2000); a thioredoxin-related oxidoreductase,
AhpC-neighboring protein D (AhpD) (Bryk et al., 2002); DlaT (for-
merly SucB) (Bryk et al., 2002; Tian et al., 2005b); and lipoamide
dehydrogenase (Lpd) (Bryk et al., 2002). DlaT and Lpd are named
for their primary roles as the E2 and E3 components of Mtb’s py-
ruvate dehydrogenase (PDH) (Tian et al., 2005b). By supplying
acetyl coenzyme A (CoA), PDH joins glycolysis to the citricll Host & Microbe 3, 137–145, March 2008 ª2008 Elsevier Inc. 137
Cell Host & Microbe
Selective Killing of Nonreplicating Mycobacteriaacid cycle, which generates high-energy phosphate bonds, re-
ducing equivalents for biosynthesis and precursors of amino
acids and heme. Acetyl CoA also serves as a building block for
the lipids in Mtb’s cell wall and a substrate for the glyoxylate
shunt, a pathway required for Mtb to persist in macrophages
and in mice (Munoz-Elias and McKinney, 2005). Thus, DlaT
may contribute to Mtb’s antinitroxidative defense by helping to
detoxify peroxynitrite (Bryk et al., 2002) and by sustaining meta-
bolic pathways required for Mtb to survive when exposed to RNI
(Rhee et al., 2005).
Herein, we demonstrated DlaT’s contribution to virulence in
experimental tuberculosis, identified a DlaT inhibitor, synthe-
sized and characterized analogs with improved properties, and
discovered a compound that can be preferentially bactericidal
against a pathogen that is not replicating.
RESULTS
Lack of Pathogenicity of DlaT-Deficient Mtb
Consistent with DlaT’s postulated roles, DdlaT (DlaT-deficient)
Mtb grew poorly in vitro, were hypersusceptible to RNI, died in
mouse macrophages, and left mice with minimal histologic evi-
dence of tuberculosis by 22 weeks after infection (Shi and Ehrt,
2006). Because the guinea pig may model human tuberculosis
better than the mouse (McMurray, 2001), we studied the course
of infection in guinea pigs after inhalation of wild-type Mtb
(H37Rv), the DdlaT mutant, and the latter strain complemented
with the wild-type allele. The two dlaT-expressing strains each
caused severe tuberculosis. In contrast, the DdlaT mutant pro-
duced low bacillary loads (Figure 1A) and did not lead to detect-
able disease (Figure 1B). All guinea pigs infected with the DdlaT
mutant had inhaled Mtb because they developed positive tuber-
culin skin tests (mean induration, 9 mm). To test the effect of
comparable initial bacterial loads, we then infected guinea pigs
with 100-fold more colony-forming units (CFU) of the DdlaT
mutant and 3-fold more of the complemented strain than of the
wild-type. The ensuing 4 weeks led to a 3.1 log10 increase in
CFU of wild-type Mtb in the lungs and a 3.1 log10 increase in
CFU of the complemented mutant, but only a mean 0.11 log10
increase for the DdlaT mutant (Figure 1C). Results were similar in
the spleen. Thus, DlaT appears to be essential for pathogenesis
by Mtb in guinea pigs.
Chemical Screen for DlaT Inhibitors
Because DdlaT Mtb grows in bacteriologic medium (Shi and
Ehrt, 2006) and Mtb’s DlaT is 29% and 39% identical to the
E2s of human PDH and a-ketoglutarate dehydrogenase, respec-
tively, DlaT would normally be dismissed as a drug target. None-
theless, the inability ofDdlaTMtb to cause disease in guinea pigs
prompted us to try to develop Mtb-selective DlaT inhibitors. We
devised a colorimetric assay for DlaT (see Figure S1 available
online) in which Lpd initiates sequential electron transfer from
NADH to DlaT to AhpD to the colorless acceptor dithionitroben-
zene (DTNB), generating yellow TNB. From a combinatorial
library of 15,000 small molecules (Chemical Diversity, Inc.) with
drug-like characteristics (Lipinski and Hopkins, 2004), we identi-
fied 34 (0.23%) as affording >50% inhibition at 10 mM or >75%
inhibition at 25 mM. Of these, 13 inhibited DlaT alone. The most
potent were rhodanines (2-thioxo-thiazolidi-4-ones) linked138 Cell Host & Microbe 3, 137–145, March 2008 ª2008 Elsevier Incthrough a chain to a carboxylic acid and joined by a methylene
bridge to a furan substituted with a halogenated aromatic. We
selected those that inhibited not only DTNB reductase (Lpd+
DlaT+AhpD) but also Mtb PDH (Lpd+DlaT+AceE). However,
the compounds in the screening collection also inhibited porcine
PDH and bound bovine serum albumin (BSA), as judged by a loss
of inhibitory activity in the presence of 100 mg/ml BSA (data not
shown). BSA that had been reduced and alkylated no longer
interfered with these rhodanines (data not shown); thus, their
binding to BSA appeared to be sulfhydryl-dependent.
Structure-Activity Relationship and Mechanism
of Inhibition
To develop more selective inhibitors, we synthesized over 1000
additional rhodanines and analyzed their structure-activity rela-
tionship (SAR) (Figure 2A; Table S1). We assessed potency by
determining the concentrations affording 50% inhibition (IC50s)
of DTNB reductase and Mtb PDH. We evaluated nonreactivity
with sulfhydryls by the relative lack of increase in IC50s for
DTNB reductase in the presence of 100 mg/ml BSA and lack of
inhibition of bovine thioredoxin reductase, an enzyme dependent
on active site cysteine and seleno-cysteine residues (Zhong
et al., 2000). Finally, we evaluated species selectivity by
Figure 1. DdlaT Is Severely Attenuated in Guinea Pigs
(A) Organ CFU in guinea pigs infected with equal inocula of Mtb H37Rv (black
bars), DdlaT (white bars), and DdlaT complemented with the wild-type allele
(gray bars), sufficient to allow recovery one day later of 135-358 CFU in lungs
of animals infected with either of the two strains encoding DlaT. In guinea pigs
infected with theDdlaT strain, no CFU were detected in 4 of 5 animals’ lungs on
day 1, or in 4 of 5 additional animals’ lungs or spleens at week 4. Horizontal line
denotes limit of detection (1.35 log10).
(B) Photomicrographs of lungs at 4 weeks postinfection.
(C) Organ CFU in guinea pigs infected with the same inoculum of wild-type Mtb
as in (A) but a 100-fold higher dose ofDdlaTMtb and a 3-fold higher dose of the
DdlaT complemented strain.
In (A) and (C), the value of the limit of detection was assigned to samples with
undetectable CFU. **p < 0.001 and *p < 0.01 by Student-Newman-Keuls test.
In (A) and (C), results are mean ± SD (n = 5) in single experiments, each of which
was repeated at least two times..
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efficacy and selectivity are summarized in Figure 2 and Table S1.
We selected compound D155931 for further study (Figure 2B;
Figure S1). Its IC50 for DTNB peroxidase (21 mM) changed little
(24 mM) in the presence of 100 mg/ml BSA. It inhibited Mtb
PDH (IC50, 45 mM) more potently than porcine PDH or thioredoxin
reductase (IC50s, >75 mM, near the limit of solubility in the re-
action buffer). For reasons explained later, we also studied its
propanolic ester, D157070 (Figure 2C), a less potent inhibitor of
DTNB peroxidase (IC50, 47 mM).
Kinetic analysis demonstrated that D155931 inhibited DlaT
competitively with AhpD (Figure 3A). Inhibition by D155931 re-
quired that DlaT be incubated with Lpd and NADH (Figure 3B),
conditions supporting DlaT’s reduction. Inhibition was time de-
pendent (Figure 3B) and irreversible upon dialysis (Figure S2).
These results suggested that D155931 bound tightly to reduced
DlaT in such a way as to interfere with DlaT’s interaction with
AhpD, while also blocking DlaT’s ability to participate in the
PDH reaction.
Selective Killing of Mycobacteria Whose Replication
Was Halted by Acid, Nitric Oxide, Hypoxia, or Tissue
Culture Medium
Next, we selected physiologic conditions that inhibited myco-
bacterial replication without reducing recoverable CFU. The fol-
lowing conditions are thought to exist in the Mtb-containing
phagosome in immunocompetent hosts: a pH of 4.5 (MacMick-
ing et al., 2003); NO diffusing from the cytosol and/or locally gen-
erated after acidification of its auto-oxidation product, nitrite
(Nathan and Ehrt, 2004); lack of leucine and lysine (Hondalus
et al., 2000; Sambandamurthy et al., 2002); minimal carbohy-
drate (Munoz-Elias and McKinney, 2005); decreased oxygen
(Voskuil et al., 2003); and limiting iron (Ferreras et al., 2005).
These inferences are supported by gene expression profiles of
Mtb recovered from macrophages in vitro (Schnappinger et al.,
Figure 2. Structures of Inhibitors
(A) Structure-activity relationship. Regioisomer (Z) orientation is based on
X-ray crystallography of D155931. Substituents are listed in order from most
to least potent (activity profile) or most to least selective for Mtb versus mam-
malian PDH (selectivity profile). Activity profile: R1 = 3-COOH > > 3-(CH2)
2COOH > 4-SO2NHCOCH3 > 4-OH > 4-SO2NH2 > 3-SO2NH2 > 3-OH >
3-COCH3 > 4-COOH; R2 = H > 4-OH > 4-Cl > 6-Cl > 6-F > 6-CH3 > 6-OCH3;
R4 = H > CH3 > > OH; Het = 2,5-furyl > > 2,5-thiazolyl > 2,6-pyridinyl > 2,5-
oxazolyl > 2,4-isoxazolyl; R3 = 4-alkyl [Alkyl: CH3, ethyl, isopropyl, tert-butyl] > >
3-isopropyl > 2, 3 or 4-Cl > 2-OCH3 > 2-methyl or ethyl > 4-Br. Selectivity
profile: R1 = 3-COOH; R2 = H; R4 = H; R3: site of substituent = 2 > > 3 > 4,
substituents = Cl F > CH3 > > OCH3 > OH > NH2; Het = 2,5-furyl.
(B) Structure of D155931 (3-((Z)-5-((5-(2-chlorophenyl)furan-2-yl)methylene)-
4-oxo-2-thioxothiazolidin-3-yl)benzoic acid).
(C) Structure of D157070 (3-hydroxypropyl 3-((Z)-5-((5-(2-chlorophenyl)furan-
2-yl)methylene)-4-oxo-2-thioxothiazolidin-3-yl)benzoate).C2003) and from lungs (Schnappinger et al., 2003; Shi et al.,
2003, 2005; Timm et al., 2003), compared to Mtb cultured in
media altered in the specified manner, along with the inability
of amino acid auxotrophs of Mtb to survive in macrophages
(Hondalus et al., 2000; Sambandamurthy et al., 2002). However,
exposure to RNI alone elicits many of the same adaptive tran-
scriptional responses in Mtb seen with depletion of amino acids,
carbohydrates, iron, or oxygen (Schnappinger et al., 2003). The
ability of NO to kill Mtb depends on concentration and time, as
illustrated with the NO-donating compound 2, 2-(hydroxynitro-
sohydrazino)-bis-ethanamine (DETANO) (Figure S3). Thus, a min-
imal set of conditions that mimics the phagosomal milieu is the
combination of weak acid and RNI. For this purpose, we used
Middlebrook 7H9 medium at pH 5.5 (approximately midway be-
tween the pH of Mtb-containing phagosomes in nonactivated
and fully activated macrophages) (MacMicking et al., 2003)
and the generation of small fluxes of NO from 0.5 mM nitrite. In
7H9 broth at pH 5.5, Bacille Calmette-Gue´rin (BCG), an attenu-
ated variant of M. bovis, stopped replicating. Mtb continued to
divide slowly unless the pH was lowered to 4.5. With the addition
of 0.5 mM nitrite to 7H9 medium at pH 5.5, Mtb also ceased
replicating. Under the latter conditions, BCG and Mtb neither
increased nor decreased in CFU over 4 days, while they
increased >20-fold in 7H9 broth at pH 6.6 without nitrite (data
not shown).
At pH 5.5, D155931 (10 mM) reduced the CFU of nonreplicating
BCG by 2 to 3 log10 without nitrite and by 4 to 5 log10 with nitrite
in a time- and concentration-dependent manner (Figures 4A
and 4B). Mtb resisted killing by nitrite (0.5 mM) alone and by
D155931 alone, but the combination led to a 2 log10 reduction
in CFU (Figure 4C). D155931 had no effect on BCG or Mtb under
replicating conditions at pH 6.6 (data not shown).
However, D155931 failed to kill intracellular BCG within pri-
mary mouse macrophages (data not shown). After comparing
several esters, we selected D157070 for study in the expectation
Figure 3. D155931 Is an Irreversible Inhibitor of DlaT Competitive
with AhpD
(A) D155931 is a competitive inhibitor of DlaT against AhpD. DTNB assay was
conducted with variable amounts of AhpD (10, 20, 30, 40, 60, 100, and 150 nM)
without (black circles) or with 7 mM (white squares), 15 mM (black triangles), and
45 mM (white triangles) D155931. Experiments were performed without prein-
cubation and were started immediately upon addition of inhibitors; initial rates
were taken from the first 5 min. Ki values of 15–18 mM were calculated from the
replots of slopes versus inhibitor concentration.
(B) D155931 is time- and substrate-dependent inhibitor of DlaT. A mixture of
Lpd, DlaT, and AhpD was preincubated with D155931 at 10 mM (diamonds),
20 mM (triangles), or 40 mM (squares) or with the vehicle control (DMSO; cir-
cles), in each case with (white symbols) or without (black symbols) 250 mM
NADH. Aliquots were withdrawn over time and tested for remaining activity
by the DTNB assay.ell Host & Microbe 3, 137–145, March 2008 ª2008 Elsevier Inc. 139
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phobicity of the compound might improve its entry into the phag-
osome, and that mycobacterial esterases might then cleave it to
release D155931. To test whether D157070 may serve as a pro-
drug for D155931, we quantified D157070 and D155931 by LC/
MS/MS after incubation with BCG. D157070 (25 mM; 4.5 mmoles
in 180 ml) incubated with 23 108 CFU/ml of BCG turned the bac-
teria yellow (Figure 5A), and we only recovered 94% of D157070
after 24 hr and 83% after 48 hr. Setting the recovered portion to
100%, the compound was distributed as follows: 30% in the me-
dium, 2%–3% in washes of the bacteria, 0.1% in the soluble por-
tion of the bacterial lysate, and 67% in the sedimentable cell
walls and membranes. We were not able to detect any
D155931 in BCG incubated with D157070. However, when we
incubated BCG with D155931 itself, the bacteria turned yellow,
indicating the presence of the rhodanine chromophore, yet re-
covery of D155931 was negligible (2% to 3%). Thus, D155931
appears to associate irreversibly with bacterial constituents. If
D157070 did give rise to D155931 inside BCG, we would not
have detected it. Although these experiments neither demon-
strated nor excluded de-esterification of D157070, they revealed
a marked proclivity of D157070 to accumulate in mycobacteria,
particularly in the cell wall. Considering only the D157070 that we
could not recover (6% at 24 hr; 17% at 48 hr), the concentration
attained in BCG cell water would be estimated at 2 to 3 mM. We
used D157070 in the remaining studies.
In 7H9 medium at pH 5.5 (conditions in which BCG does not
replicate), D157070 reduced BCG CFU by 1.5 log10 in the ab-
sence and by 2.5 to 3 log10 in the presence of 0.5 mM nitrite
(Figure 5B). D157070 also killed BCG at nearly neutral pH
when replication was inhibited by sublethal concentrations of
Figure 4. D155931 Kills Nonreplicating Mycobacteria
(A) Killing of BCG by D155931 was time dependent and synergistic with nitrite.
BCG was treated at pH 5.5 (which prevents its replication) with 10 mM D155931
(squares) or DMSO (circles) without (black symbols) or with (white symbols)
0.5 mM nitrite for 4 days. Nitrite alone at this concentration caused no killing.
(B) Killing of BCG by D155931 was concentration-dependent. BCG was
treated with D155931 at pH 5.5 without (black symbols) or with 0.5 mM nitrite
(white symbols) for 4 days. Dashed line denotes inoculum.
(C) D155931 only killed nonreplicating Mtb synergistically with nitrite. Mtb
H37Rv was treated for 4 days with D155931 at pH 5.5 (which does not prevent
its replication) without (black symbols) or with 0.5 mM nitrite (white symbols).
Dashed line denotes inoculum. Results are means ± SD of triplicates in single
experiments, each of which was repeated at least two times.140 Cell Host & Microbe 3, 137–145, March 2008 ª2008 Elsevier IncFigure 5. D157070 Kills Nonreplicating Mycobacteria
(A) The yellow compounds D155931 (25 mM) and D157070 (25 mM) partitioned
from the medium into BCG over 24 hr at pH 6.6, as evidenced by the color of
the bacteria collected by centrifugation as compared to BCG exposed to
vehicle alone.
(B) Killing of BCG by D157070 was concentration dependent and synergis-
tic with nitrite. BCG was treated at pH 5.5 (which prevents its replication)
without (black symbols) or with 0.5 mM nitrite (white symbols) for 4 days.
Nitrite alone at this concentration caused no killing. Dashed line denotes
inoculum.
(C) D157070 killed BCG at pH 6.6 in the presence of 50 mM DETANO (white
symbols), which generates sublethal NO, but not DETA (black symbols).
Dashed line denotes inoculum. DETANO or DETA were added at 0, 24, 48,
and 72 hr.
(D) D157070 killed Mtb synergistically with nitrite. Mtb was treated with
D157070 at pH 5.5 (black circles), pH 5.5 + 0.5 mM nitrite (white circles), or
at pH 6.6 (black squares) for 4 days. Inocula were 6.6 3 107 (pH 5.5) and
5.9 3 107 (pH 6.6) CFU/ml.
(E) D157070 killed mycobacteria in Dulbecco’s modified Eagle’s medium with
10% FBS (‘‘complete medium’’), which did not support mycobacterial replica-
tion. BCG (black symbols) or Mtb (white symbols) were inoculated at 8 3 105
(BCG) or 1.5 3 105 (Mtb) CFU/ml into complete medium and treated with
D157070 for 4 days.
(F) D157070 killed hypoxic Mtb. Mtb was treated with rifampin (1 mg/ml),
isoniazid (INH) (0.4 mg/ml), D157070 (12.5 mg/ml), or DMSO for 4 days after
reaching stage 2 nonreplicative persistence (Wayne and Hayes, 1996). Results
are means ± SD of triplicates in single experiments, each of which was
repeated at least two times.
(G) D157070, but not isoniazid, killed hypoxic Mtb with butyrate instead of car-
bohydrate as a carbon source. Mtb was treated with D157070 (12.5 mg/ml)
(white circles), isoniazid (0.1 mg/ml) (black circles), or DMSO (white squares)
for 4 or 6 days in environmental chambers at 1% O2, pH 5.5 with 0.3 mM
NO2. Results are mean ± SD of triplicates in single experiments, each of which
was repeated at least two times..
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Mtb at pH 5.5 (conditions in which Mtb replicates) but reduced
the number of viable Mtb by 1.5 log10 in the presence of sublethal
nitrite (conditions in which Mtb does not replicate) (Figure 5D).
Under growth-sustaining conditions in bacteriologic medium
7H9 at pH 6.6, D157070 had no effect on the viability of BCG
(data not shown) or Mtb (Figure 5D). In contrast, D157070 killed
BCG and Mtb in Dulbecco’s modified Eagle’s medium with 10%
fetal bovine serum at pH 7.4 (Figure 5E), a medium that mimics
human extracellular fluid but does not support the replication
of Mtb.
To further test the dependence of bactericidal activity on the
microbe’s nonreplicative state, we added D157070 to Mtb in
Dubos broth at pH 6.6 in the Wayne model of hypoxia (Wayne
and Hayes, 1996). Under conditions of stage 2 nonreplicative
persistence, D157070 (25 mM; 12.5 mg/ml) reduced the number of
viable Mtb by 2 log10 within 4 days of exposure (Figure 5F). As a
positive control, we included rifampin (1.2 mM; 1 mg/ml), the only
standard chemotherapeutic effective against hypoxic Mtb in vitro
(Zhang, 2005). Isoniazid (2.9mM; 0.4mg/ml), which is effective only
against replicating Mtb, served as a negative control (Figure 5F).
Finally, we subjected Mtb to a model of nonreplicating persis-
tence that we have developed in our lab. It comprises four con-
ditions introduced simultaneously, each of which can prevent
Mtb from replicating and each of which is thought to mimic the
environment encountered by some populations of Mtb in an
infected host: moderate hypoxia (1% O2), replacement of car-
bohydrate with fatty acid as a carbon source (modified Sauton’s
medium with 0.05% butyrate), mild acidity (pH 5.5), and low-
level nitrite (0.3 mM). In combination, these conditions caused
5 3 106 Mtb Erdman to decline in viability about 0.4 log10 over 6
days. Exposure to isoniazid (0.1 mg/ml) during that period had no
discernibleeffect. Incontrast,D157070 (25mM;12.5mg/ml) reduced
the number of viable Mtb by nearly another 2 log10 (Figure 5G).
Evidence that D157070 Kills Mycobacteria
in a DlaT-Dependent Manner
In the presence of sublethal nitrite at pH 5.5, Mtb lacking DlaT
was almost completely spared by 10 mM D157070 (Figure 6A),
while wild-type Mtb (Figure 5D) and the mutant strain comple-
mented with the wild-type allele of dlaT (Figure 6B) were both
susceptible. Thus, an Mtb strain with a genetic lack of DlaT
was resistant to killing by D157070, and sensitivity was restored
when DlaT was expressed.
We considered three possible explanations for the fact that
susceptibility to D157070 was DlaT-dependent. First, DlaT could
be activating the compound to its bactericidal form. However,
upon treatment of mycobacteria with D157070, we could quan-
titatively recover the parent compound, but no metabolites aris-
ing from it. Second, after reacting with D157070, DlaT might
acquire the ability to inhibit another enzyme, such as its binding
partner, Lpd. We could find no evidence for this (data not shown),
but cannot exclude such an effect on an enzyme we did not test.
Third, mycobacteria that have adapted to the presence of DlaT
may be killed when DlaT is acutely inhibited, while those that
can only grow by adapting to the absence of DlaT may not be
vulnerable to a DlaT inhibitor.
To explore the possibility that DlaT is inhibited in vivo by
D157070, we tested whether we could detect accumulation ofCepyruvate in Mtb grown on glucose and glycerol after treatment
with D157070. We reasoned that inhibition of DlaT would result
in PDH inhibition, followed by accumulation of pyruvate and
intermediary metabolites upstream of PDH. Given the lability of
many of the glycolytic and tricarboxylic acid (TCA) cycle metab-
olites (Tian et al., 2005a), we were unable to detect pyruvate but
instead quantified free amino acids, many of which arise from the
TCA cycle. We could quantify 13 of the 20 amino acids in Mtb ly-
sates. When we added D157070 to wild-type Mtb or the comple-
mented mutant (DdlaT pMV306dlaT) grown on glucose and glyc-
erol in the presence of sublethal nitrite at pH 5.5, the only
consistently observed change was elevation of valine, a metabo-
lite of pyruvate (Figure 6C). In DdlaT Mtb, the valine level did not
change upon exposure to D157070 (Figure 6C), though the base-
line level of alanine, another major metabolite of pyruvate, was
higher than in wild-type or complemented strains (data not
shown). These results support the inference that DlaT is inhibited
by D157070 in intact Mtb. These results also underscore that
genetic absence of DlaT affected Mtb’s intermediary metabolism
differently than acute treatment with a DlaT inhibitor.
Impact of D157070 on Mycobacteria
within Macrophages
When applied to cultures of infected bone marrow-derived
mouse macrophages (BMM) for 2 days, D157070 (5 mM) reduced
the number of viable Mtb by 2.5 log10 CFU (Figure 7A), thus
overcoming the ineffectiveness of the parent compound,
Figure 6. Killing of Mtb by D157070 Is DlaT-Dependent
DdlaT Mtb (A) or the complemented mutant (DdlaT pMV306dlaT) (B) were
treated for 4 days with D157070 at pH 5.5 without (black symbols) or with
0.5 mM nitrite (white symbols). Dashed lines denote inocula (6.63 107 CFU/ml
for DdlaT and 5.7 3 107 CFU/ml for DdlaT pMV306dlaT). Results in (A) and (B)
are mean ± SD of triplicates in single experiments, each of which was repeated
at least two times.
(C) Intracellular levels of valine increased in wild-type and DdlaT pMV306dlaT
Mtb, but not in DdlaT, upon treatment with D157070 (10 mM; white bars) as
compared to DMSO-treated controls (black bars). Results are mean ± SD
from three independent experiments. The following differences in levels of va-
line were statistically significant (p < 0.05) by Student’s t test: D157070-treated
wild-type Mtb versus untreated wild-type; and D157070-treated comple-
mented strain versus untreated complemented strain.ll Host & Microbe 3, 137–145, March 2008 ª2008 Elsevier Inc. 141
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Selective Killing of Nonreplicating MycobacteriaD155931, on mycobacteria residing in macrophages. D157070
also killed BCG in mouse BMM in a dose- (data not shown)
and time-dependent manner (Figure 7B). Although D157070 (5
mM) achieved 2 log10 reduction in CFU by day 1, BCG appeared
to regain some of its replicative potential when recovered from
macrophages on day 4. This suggested that upon exposure to
D157070, BMM may upregulate multidrug resistance (MDR)
export pumps, so that intracellular concentrations of D157070
in macrophages initially rose and then declined. Treatment of
BCG-infected BMM with a combination of D157070 and verap-
amil, an MDR pump inhibitor, led to >2 log10 killing of BCG by
day 1, and this was sustained for 4 days, the duration of the
experiment (Figure 7B). Verapamil alone had no effect on BCG
in culture or in BMM. Enhanced intracellular accumulation of
D157070 in the presence of verapamil was confirmed micro-
scopically by the coloration of the cells (data not shown).
D157070 was nontoxic to the BMM during the treatment, as
judged by morphology and trypan blue exclusion (data not
shown). Similarly, there was little or no morphologic or metabolic
evidence of toxicity of D157070 to primary human lung and skin
fibroblasts and Vero monkey kidney cells at up to 30 mM over
48 hr (Figure 7C).
DISCUSSION
The inability of DdlaT Mtb to cause tuberculosis in the guinea pig
validates DlaT as a target. We could not have predicted this de-
Figure 7. D157070 Kills BCG andMtb inMouse BoneMarrowMacro-
phages but Spares Mammalian Cells
(A) BMM infected with Mtb were treated with D157070 at 5 mM (black bar) or
with DMSO (white bar) beginning after a 4 hr period of infection (day 0) with
Mtb (3.8 3 104 CFU/ml). Medium and compound were replaced on day 1.
On day 2, the monolayers were lysed, and CFU were determined.
(B) BMM infected with BCG were treated with D157070 at 5 mM (white circles)
or with DMSO (black circles) or with a combination of D157070 (5 mM) and ve-
rapamil (50 mM) (black squares) beginning after a 4 hr period of infection (day 0)
with BCG (13 104 CFU/ml). Medium and compounds were replaced on day 2.
(C) Primary human fibroblasts from lung (triangles) or skin (squares) and
monkey kidney Vero cells (circles) were treated with D157070 at the indicated
concentrations for 48 hr and assessed for viability by MTS assay.
Results are mean ± SD of triplicates in single experiments, each of which was
repeated at least two times. *p < 0.05 by unpaired t test.142 Cell Host & Microbe 3, 137–145, March 2008 ª2008 Elsevier Incgree of attenuation from the phenotype of DdlaT Mtb in bacteri-
ologic growth medium or mice (Shi and Ehrt, 2006). It will be im-
portant to learn more about the intermediary metabolism of Mtb
in mice, guinea pigs, and humans and the levels of nitroxidative
stress that Mtb faces in these hosts.
We have identified the rhodanine D155931 as an irreversible,
substrate-dependent, time-dependent inhibitor of Mtb’s DlaT
and DlaT-dependent peroxynitrite reductase-peroxidase and
PDH. Its propanolic ester, D157070, partitioned from aqueous
media into mycobacteria and killed Mtb within macrophages.
D155931 and D157070 killed mycobacteria only when the bacte-
ria were precluded from replicating (Table 1). Inhibition of repli-
cation could be afforded by sublethal levels of acid, RNI, or
hypoxia; by combinations of these with deprivation of carbohy-
drate and provision of fatty acid as a carbon source; or by incu-
bation in a culture medium optimized for mammalian cells. These
findings suggest new approaches to the search for chemothera-
peutics useful in persistent infections. For example, these in-
hibitors could not have been identified had we screened for
mycobactericidal activity in a bacteriologic growth medium, as
anti-infectives are customarily sought. In contrast, we presum-
ably could have identified them by screening for compounds
that kill mycobacteria in a medium resembling human extracellu-
lar fluid.
Anti-infectives may kill a nonreplicating pathogen in at least
two ways: by inhibiting metabolic processes that the pathogen
needs to sustain viability or by inhibiting pathways of detoxifica-
tion or repair that the pathogen uses to protect itself from steril-
ization by the host chemistry that prevents it from replicating.
Inhibitors of Mtb’s DlaT may act by both mechanisms. To our
knowledge, the synergy between the compounds studied here
and host antimicrobial factors such as RNI and acid has only
one precedent among clinically approved anti-infectives, in
that pyrazinamide kills Mtb preferentially at low pH (Zhang,
2005). Pyrazinamide sterilizing activity is also remarkable in
that it increases as Mtb enters dormancy in very late stationary
phase, as modeled by Hu, Coates, and Mitchison (Hu et al.,
2006). Only one standard anti-mycobacterial agent, rifampin, is
effective under hypoxic conditions in vitro, although some exper-
imental compounds share this property (Stover et al., 2000).
Our studies raise the surprising possibility that PDH may be
less critical to the survival of replicating than nonreplicating my-
cobacteria. Perhaps alternative metabolic pathways are more
readily available to mycobacteria under growth conditions than
Table 1. Summary of Rhodanine Effects on Mycobacteria
D155931 (mM)a D157070 (mM)a
Condition BCG Mtb BCG Mtb
7H9, pH 6.6 NE NE NE NE
7H9, pH 6.6 + DETANO - - 1 -
7H9, pH 5.5 10 NE 15 NE
7H9, pH 5.5 + NO2
 3 15 2 10
DMEM-10%FBS, pH 7.4 - - 4 >10
Hypoxia, NRP-2 - - - 25
Mouse BMMs NE NE 5 5
-, not tested; NE, no effect.
a Concentration at which 2 log10 killing is observed..
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ever, such inferences are complicated by partial discrepancies
between the phenotypes ofDdlaTMtb and wild-type Mtb treated
with D157070. Both DdlaT Mtb and wild-type Mtb treated with
D157070 survived at pH 5.5 in the absence of RNI. At pH 5.5,
3 mM nitrite killed the DdlaT mutant more extensively than
wild-type Mtb (Shi and Ehrt, 2006). D157070-treated wild-type
Mtb succumbed to 0.5 mM nitrite, which spared untreated
Mtb. Thus, knockout of the gene and treatment with an inhibitor
of the enzyme both increased Mtb’s sensitivity to nitrite, but not
to the same extent. D157070 had very little mycobactericidal ef-
fect on Mtb that lacked DlaT. Likewise, the level of valine inDdlaT
Mtb did not rise in response to D157070 as it did in wild-type Mtb
and the complemented mutant. Yet, the basal level of valine dif-
fered markedly in DdlaT Mtb from that in the D157070-treated
wild-type and complemented strains.
At least two explanations for these discrepancies are likely.
First, the DdlaT mutant may have adapted to prolonged DlaT de-
ficiency by upregulating compensatory pathways of metabolism
and anti-RNI defense. Second, it is common that chemical inhib-
itors have more than one target in living organisms. Various rho-
danines with different substituents than those studied here were
reported to inhibit a wide range of targets, including protein tyro-
sine phosphatases (Cutshall et al., 2005), Klebsiella UDP-galac-
topyranose mutase (Soltero-Higgin et al., 2004), viral (Powers
et al., 2006) and bacterial (Gualtieri et al., 2006) RNA polymerase,
and Plasmodium enoyl-acyl carrier protein reductase (Kumar
et al., 2007). D157070 is likely to have (an) additional target(s) in
Mtb besides DlaT, in particular because it accumulates in myco-
bacteria to very high concentrations. Efforts to identify additional
targets are underway. Irrespective of the specific antimyco-
bacterial targets of D157070, it is clear that the ability of
D157070 to kill nonreplicating mycobacteria is DlaT-dependent.
Some authorities have argued that ‘‘the dependence of front-
line anti-TB drugs on actively replicating cells for activity is prob-
ably the greatest limitation of current therapy’’ (Warner and
Mizrahi, 2006). According to this view, more agents that kill
nonreplicating Mtb are needed to shorten the time it takes to
treat active tuberculosis (Duncan and Barry, 2004). Treatment
of latent Mtb infection is a critical need in its own right, because
latent Mtb infection sustains the pandemic: nearly 9 million la-
tently infected people develop active tuberculosis per year,
each of whom infects an estimated 10–15 other people per
year before being isolated, responding to treatment, or dying
(World Health Organization, 2006).
Several clinically proven (rifampin) (Zhang, 2005) and experi-
mental agents (Stover et al., 2000) kill nonreplicating Mtb. How-
ever, they kill replicating Mtb better. This is a useful property.
Nonetheless, it has reinforced the presumption that anti-infective
compounds must necessarily be more effective against replicat-
ing than nonreplicating bacterial pathogens. The most important
result of this work is to show that the opposite is possible, lend-
ing strong support to the argument of Coates and Hu (Coates
and Hu, 2007) that screens should be undertaken for agents
that kill nonreplicating pathogens. Given suitable pharmaceuti-
cal properties, such agents could be used for prophylaxis in
individuals with latent Mtb infection, and could be combined
with conventional agents to shorten the treatment of clinically
active tuberculosis.CeEXPERIMENTAL PROCEDURES
Recombinant AhpD, DlaT, and Lpd from Mtb were expressed in E. coli and pu-
rified as reported (Argyrou and Blanchard, 2001; Bryk et al., 2002). A combina-
torial library of 15,000 small molecules with drug-like characteristics covering
125 different templates from Chemical Diversity, Inc. was used for screen.
Compounds in DMSO or the vehicle alone as a control were robotically dis-
pensed to Falcon Microtest 384-well plates containing a mixture of the 3 en-
zymes (Lpd, 200 nM; DlaT, 350 nM; AhpD, 36 nM). After a 30 min preincubation
with inhibitors, an equal volume of the reaction mix (NADH, 200 mM; DTNB,
150 mM; EDTA, 2 mM; potassium phosphate, 100 mM; pH 7.0) was added. Optical
density was recorded at 405 nm at 0 and 30 min. We selected compounds pro-
ducing 50% (7, 000 compounds tested at 10 mM) or 75% (8,000 compounds
tested at 25 mM) inhibition, confirmed their activity after resupply and resynthe-
sis, and identified each as inhibiting either AhpD, Lpd, or DlaT by separate as-
says. Lpd inhibitors were identified by inhibition of lipoamide-dependent
NADH consumption. DlaT inhibitors were identified in Lpd/DlaT-dependent
DTNB assay. Kinetic analyses were carried out with the DTNB peroxidase as-
say. Bovine thioredoxin reductase was purified as described (Zhong et al.,
2000) and assayed with 100 mM NADPH and 75 mM DTNB. PDH activity was
measured in 50 mM KPi, pH 7.0, 1 mM NAD+, 200 mM thiamine pyrophosphate,
1 mM MgCl2, 1 mM pyruvate and 170 mM CoA with a mixture of 100 nM Lpd,
175 nM DlaT and 100 nM AceE (for Mtb’s PDH), or with porcine PDH (Sigma)
after removing BSA on Sephadex G100. NADH formation was monitored at
340 nm for 5 min.
Mtb H37Rv (ATCC 25618) and M. bovis BCG (ATCC 35734) were cultivated
in Middlebrook 7H9 broth, pH 6.6 with 0.2% glycerol, 0.05% Tween 80 and
10% ADN (0.5% BSA, 2% dextrose, 0.85% NaCl). Where indicated, we also
tested Mtb Erdman. CFU were enumerated on Middlebrook 7H11 agar plates
with 10% Middlebrook OADC enrichment. Midlog cultures (A580 0.8–1.0) were
prepared as single cell suspensions in 7H9 at pH 5.5, diluted to 0.1 (A580). My-
cobacteria were incubated under indicated test conditions in 96-well plates in
200 ml and plated for CFU after serial dilution in 7H9, pH 6.6. Lysates were pre-
pared as described (Bryk et al., 2002), and protein was determined by the
Bradford method. Hypoxic conditions were achieved as specified by Wayne
and Hayes (Wayne and Hayes, 1996). Decoloration of methylene blue in con-
trol tubes by 12–14 days indicated stage 2 nonreplicative persistence. On day
18, control tubes were cultured and experimental tubes received DMSO,
D157070, isoniazid, or rifampin by injection through seals, which were then
reinforced with wax. Experimental tubes were plated 4 days after injection of
compounds. Hypoxic conditions (1% O2) in experiments with butyrate as a car-
bon source were achieved in environmental chambers from BD Biosciences.
For these experiments, Mtb Erdman was treated with D157070 (25 mM) or iso-
niazid (0.1 mg/ml) for 4 and 6 days in modified Sauton’s medium (0.1% NH4Cl,
0.005% ferric ammonium citrate) with 10% AN (0.5% BSA, 0.85% NaCl),
0.02% tyloxapol, 0.05% butyrate at pH 5.5 in the presence of 0.3 mM NaNO2.
Intracellular levels of amino acids (AA) were determined on 15 ml cultures of
Mtb inoculated at A580 0.1 in 7H9 at pH 5.5 with 0.5 mM NaNO2 with or without
10 mM D157070. After 24 hr, metabolism was interrupted by rapid cooling.
Bacteria were pelleted at 4C and washed twice with ice-cold PBS, 0.05%
Tween 80. No AA were detectable in supernatants or washes. Lysates were
prepared by mechanical disruption and normalized according to protein con-
centration by Bradford assay. AA were extracted as described (Khan et al.,
1991), and levels were determined by o-phthaldialdehyde derivatization and
reverse phase high-performance liquid chromatography with fluorescent
detection (Henderson et al., 2000).
BMMs differentiated for 7 days as described (Shi and Ehrt, 2006) were re-
moved from the original cultures and replated at 1 3 105 cell/well in 48-well
plates in 0.5 ml of DMEM with 4.5 g/l glucose, 0.584 g/l L-glutamine, 1 mM py-
ruvate, 10% FBS, and 10% L-cell conditioned medium (‘‘complete medium’’).
One day later, 105 mycobacteria were added. Four hours later, monolayers
were washed twice in PBS. Complete medium (0.5 ml) with inhibitors or
DMSO as a control was added and replaced daily (for Mtb-infected cells) or
on days 2 and 4 (for BCG-infected cells). On indicated days, monolayers
were lysed in PBS with 0.5% Triton X-100 for CFU determination. Macrophage
viability was monitored by photomicroscopy, trypan blue exclusion, and/or
staining with ethidium homodimer and calcein AM (Invitrogen). Primary, diploid
human lung (ATCC CCL-171) and skin (ATCC CRL-2522) fibroblasts andll Host & Microbe 3, 137–145, March 2008 ª2008 Elsevier Inc. 143
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Selective Killing of Nonreplicating Mycobacteriamonkey kidney Vero 76 cells (ATCC CRL-1587) were incubated with test com-
pounds for 24 hr in complete medium, and viability was assessed by photomi-
croscopy and MTS tetrazolium reduction assay (Invitrogen).
Guinea pig studies and the synthesis, structural confirmation, purity, and
assay of D155931 and D157070 are described in the Supplemental Data avail-
able with this article online.
SUPPLEMENTAL DATA
The Supplemental Data include Supplemental Experimental Procedures, three
supplemental figures, and one supplemental table and can be found with this
article online at http://www.cellhostandmicrobe.com/cgi/content/full/3/3/137/
DC1/.
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